Targeted Therapy
253 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Targeted Therapy (253)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Gedatolisib |
PI3K Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Gedatolisib
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
||||
Gefitinib |
EGFR / HER2 Tyrosine Kinase Inhibitor | Solid Tumour | ||
|
Molecule
Gefitinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
||||
Gilteritinib |
FLT3 Inhibitor | Hematologic (AML) | ||
|
Molecule
Gilteritinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
||||
Givinostat |
HDAC Inhibitor | Hematologic (Lymphoma) | ||
|
Molecule
Givinostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
||||
Glasdegib |
Hedgehog Pathway Inhibitor | Solid Tumour / Hematologic (AML) | ||
|
Molecule
Glasdegib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour / Hematologic (AML)
Drug Class / Mechanism
Hedgehog Pathway Inhibitor |
||||
Glecirasib |
RET / MET / KRAS / IDH Inhibitor | Solid Tumour | ||
|
Molecule
Glecirasib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
||||
Glumetinib |
MET Inhibitor | Solid Tumour | ||
|
Molecule
Glumetinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
MET Inhibitor |
||||
Golvatinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Golvatinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Icotinib |
EGFR / HER2 Tyrosine Kinase Inhibitor | Solid Tumour | ||
|
Molecule
Icotinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
||||
Idasanutlin |
MDM2 Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Idasanutlin
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
MDM2 Inhibitor |
||||
Idelalisib |
PI3K Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Idelalisib
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
||||
Ilginatinib |
JAK Inhibitor | Hematologic (MPN) | ||
|
Molecule
Ilginatinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
||||
GedatolisibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
|
GefitinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
|
GilteritinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
|
GivinostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
|
GlasdegibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour / Hematologic (AML)
Drug Class / Mechanism
Hedgehog Pathway Inhibitor |
|
GlecirasibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
|
GlumetinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
MET Inhibitor |
|
GolvatinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
IcotinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
|
IdasanutlinTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
MDM2 Inhibitor |
|
IdelalisibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
|
IlginatinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
|